1647 Ife



PATENT Attorney Docket No. UDL-007

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Kinrade et al.

**CONFIRMATION NO.:** 

9691

**SERIAL NO:** 

09/771,956

**GROUP NO.:** 

1647

FILING DATE:

January 29, 2001

**EXAMINER:** 

Wegert, S.

TITLE:

CHIMERIC NEUROPEPTIDE Y RECEPTORS

# CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, and any document(s) referred to as enclosed herein, is/are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this day of August, 2004.

Lisa Marie Solis

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450


Sir:

### Submitted herewith are:

- 1. Transmittal Form (1 page);
- 2. Supplemental Information Disclosure Statement (2 pages); and
- 3. Form PTO-1449 (1 page);
- 4. Copy of cited references A8, B6 and C1-C2; and
- 5. A Return Receipt Postcard.

3110940-1

	PEVO									
<b>7</b> ς			Application	Serial Number		09/771,956				
{	AUG 27 2004 5		Filing Date			January 29, 2001				
$  \setminus $			First Named	Inventor		Kinrade				
`	TRANSMITTA	Τ.	Group Art Unit			1647				
			Examiner N	ame		Wegert, S.				
	FORM		Attorney Do	ocket No.		UDL-007				
			Patent No.			Not yet assigned				
			Issue Date			Not yet assigned				
		. EN	CLOSURES (c	heck all that apply)						
	Fee Transmittal Form		Copy of Notic	e to File Missing		Notice of Appeal to Board				
	☐ Check Attached		Parts of Appli	cation		of Patent Appeals and Interferences				
	Copy of Fee Transmittal Form		Formal Drawin	ng(s)		Appeal Brief (in triplicate)				
	Amendment/Response		Request For C Examination (			Status Inquiry				
	☐ Preliminary ☐ After Final		Transmittal			Return Receipt Postcard				
	☐ Affidavits/declaration(s) ☐ Letter to Official ☐ Draftsperson		Power of Attor (Revocation of	rney f Prior Powers)		Certificate of First Class Mailing under 37 C.F.R. 1.8				
	including Drawings [Total Sheets]		Terminal Disc	laimer		Certificate of Facsimile Transmission under 37 C.F.R. 1.8				
	Petition for Extension of Time			aration and Power r Utility or Design tion		Additional Enclosure(s) (please identify below)				
⊠	Supplemental Information Disclosure Statement		Small Entity S	tatement						
	Form PTO-1449 Copies of IDS Citations A8, B6 and C1-C2		CD(s) for large table or computer program							
	Certified Copy of Priority Document(s)			fter Allowance						
	Sequence Listing submission Paper Copy/CD Computer Readable Copy Statement verifying identity of above		Request for Co Correction Certificate duplicate)	ertificate of of Correction (in						
COI	RRESPONDENCE ADDRESS			SIGNATURE BL	oc					
Direct all correspondence to: Patent Administ Testa, Hurwitz & High Street Tov 125 High Street Boston, MA 02 Tel. No.: (617) & Fax No.: (617) &			hibeault, LLP	Date: August <b>25</b> , 200 <sup>4</sup> Reg. No. 45,508 Tel. No.: (617) 248-72 Fax No.: (617) 248-71		Daniel A. Wilson Attorney for Applicants				





## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Kinrade et al.

**CONFIRMATION NO.:** 

9691

SERIAL NO:

09/771,956

**GROUP NO.:** 

1647

FILING DATE:

January 29, 2001

**EXAMINER:** 

Wegert, S.

TITLE:

CHIMERIC NEUROPEPTIDE Y RECEPTORS

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the patents and publications are enclosed. Applicants note that a Supplementary Partial European Search Report for European Patent Application No. 01 09 91 4335 (Reference C2) is enclosed for the Examiner's consideration.

### **REMARKS**

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

(1)	within three (3) months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. 1.114; or
(2)	after the period defined in (1) but before the mailing date of a final action or a notice of allowance under 37 C.F.R. 1.311, and
	the requisite Statement is below, OR
	the requisite fee under 37 C.F.R. 1.17(p), namely \$180.00, is included herein, or

Supplemental Information Disclosure Statement Serial No. 09/771,956 Page 2 of 2

(3)	after the mailing date of a final action or notice of allowance but before the payment of the issue fee, AND
	the requisite Statement is below, AND
	the requisite petition fee under 37 C.F.R. 1.17(p), namely \$180.00 is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

#### **STATEMENT**

As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that [check the appropriate space only if either (2) or (3) is checked on the previous page and the Statement is required]:

- 1. Each item of information contained in the Information Disclosure

  Statement was first cited in any communication from a foreign patent

  office in a counterpart foreign application not more than three months

  prior to the filing of the Information Disclosure Statement; or
- No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Date: August <u>25</u>, 2004 Reg. No. 45,508

Tel. No.: (617) 248-7226 Fax No.: (617) 248-7100

3110939-1

Respectfully submitted,

Daniel A. Wilson

Attorney for the Applicants Testa, Hurwitz & Thibeault, LLP

High Street Tower 125 High Street

Boston, Massachusetts 02110



**FORM PTO - 1449** 

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: UDL-007

APPLICANT(S): Kinrade et al.

SERIAL NO.: 09/771,956

FILING DATE: January 29, 2001

GROUP NO.: 1647

GROUP NO.: 1647												
			U.S.	PATEN	IT D	OCUME	ENTS					
EXAM. INIT.		DOCUMENT NUMBER	DATE	NA	NAME			CLASS		ss	FILING DATE IF APPROPRIATE	
<del>,</del>	A8	6,399,631 B1	06/04/200	2 Elli	iott <i>et</i>	al.					07/21/2000	
			FOREI	GN PAT	ENT	DOCU	MEN7	ΓS				
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNT	RY	CLASS SU CL			LING ABSTRACT ONLY			ENGLISH LANG (Y/N)
	В6	WO97/37998	10/16/1997	PCT					N			Y
EXAMI	NER		•			DATE C	ONSIL	DERED				• · · · · · · · · · · · · · · · · · · ·
			OTHER AR	T, JOU	RNA	L ARTI	CLES	, ETC.				
EXAM. INIT.	ОТН	IER DOCUMENT	S: (Including A	Author, Ti	itle, D	ate, Relev	ant Pa	ges, Place	e of Pu	blica	tion)	
	C1 Dohlman et al., "Model Systems for the Study of Seven-Transmembrane-Segment Receptors," Annu. Rev. Biochem., 60:653-88 (1991).											
	C2 Supplementary Partial European Search Report for European Patent Application No. 01 91 4335, dated March 26, 2004.											
EXAMINER					DATE CONSIDERED							

3110937-1